Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

Table 1 Baseline characteristics of patients observed in the study (n = 52) and included in groups treated with the sodium-glucose co-transporter-2 inhibitors or other glucose lowering drugs

Variable	SGLT2-I (n = 26)	OTHER (n = 26)	P value
Age (yr)	60.6 ± 6.78	63.4 ± 10.4	0.246
Sex (male/female)	15/11	15/11	1.000
BMI (kg/m2)	34.8 ± 7.7	34.5 ± 5.9	0.875
No comorbidities, n (%)	2 (7.7)	2 (7.7)	1.000
Dyslipidemia, n (%)	13 (50.0)	15 (57.7)	0.578
Hypertension, n (%)	10 (38.5)	15 (57.7)	0.165
Chronic heart failure, n (%)	8 (30.8)	3 (11.5)	0.089
Chronic kidney disease, n (%)	9 (34.6)	4 (15.4)	0.109
AST (U/L)	48.5 ± 26.6	54.7 ± 13.3	0.293
ALT (U/L)	49.6 ± 39.2	65.0 ± 18.7	0.077
Gamma-GT (U/L)	151.3 ± 87.2	179.2 ± 56.9	0.178
Tryglycerides (mg/dL)	140.2 ± 45.9	133.5 ± 33.2	0.549
Fasting glucose (mg/dL)	150.1 ± 45.9	159.7 ± 49.8	0.473
HbA1c (%)	9.24 ± 3.01	8.73 ± 2.31	0.496
Creatininemia (mg/dL)	1.01 ± 0.44	0.88 ± 0.32	0.229
eGFR (mL/min/1.73 m2)	61.4 ± 38.9	73.2 ± 24.6	0.197
Albuminemia (g/dL)	3.91 ± 0.44	4.08 ± 0.47	0.184
Platelets (n, × 103/mm3)	175.7 ± 113.1	179.7 ± 76.7	0.882

BMI: Body mass index; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; Gamma-GT: Gamma-glutamyl transpeptidase; HbA1c: Hemoglobin A1c; eGFR: Epidermal growth factor receptor; SGLT2-I: Sodium-glucose co-transporter-2 inhibitor; OTHER: Other glucose lowering drug.